Cargando…

Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: The dose of supplemental vitamin D needed in infants born with serum 25-hydroxyvitamin D (25[OH]D) concentrations less than 50 nmol/L (ie, 20 ng/mL) is unclear. OBJECTIVE: To determine whether a higher dose (1000 IU vs 400 IU per day) is required in infants born with 25(OH)D concentratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gharibeh, Nathalie, Razaghi, Maryam, Vanstone, Catherine A., Sotunde, Olusola F., Glenn, Laura, Mullahoo, Kristina, Farahnak, Zahra, Khamessan, Ali, Wei, Shu Qin, McNally, Dayre, Rauch, Frank, Jones, Glenville, Kaufmann, Martin, Weiler, Hope A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926359/
https://www.ncbi.nlm.nih.gov/pubmed/36780180
http://dx.doi.org/10.1001/jamapediatrics.2022.5837
_version_ 1784888262419021824
author Gharibeh, Nathalie
Razaghi, Maryam
Vanstone, Catherine A.
Sotunde, Olusola F.
Glenn, Laura
Mullahoo, Kristina
Farahnak, Zahra
Khamessan, Ali
Wei, Shu Qin
McNally, Dayre
Rauch, Frank
Jones, Glenville
Kaufmann, Martin
Weiler, Hope A.
author_facet Gharibeh, Nathalie
Razaghi, Maryam
Vanstone, Catherine A.
Sotunde, Olusola F.
Glenn, Laura
Mullahoo, Kristina
Farahnak, Zahra
Khamessan, Ali
Wei, Shu Qin
McNally, Dayre
Rauch, Frank
Jones, Glenville
Kaufmann, Martin
Weiler, Hope A.
author_sort Gharibeh, Nathalie
collection PubMed
description IMPORTANCE: The dose of supplemental vitamin D needed in infants born with serum 25-hydroxyvitamin D (25[OH]D) concentrations less than 50 nmol/L (ie, 20 ng/mL) is unclear. OBJECTIVE: To determine whether a higher dose (1000 IU vs 400 IU per day) is required in infants born with 25(OH)D concentrations less than 50 nmol/L for bone mineral accretion across infancy. DESIGN, SETTING, AND PARTICIPANTS: In this prespecified secondary analysis of a double-blinded randomized clinical trial, conducted from March 2016 to March 2019 in a single center in Greater Montreal, Quebec, Canada, a consecutive sample of 139 healthy term singletons were recruited from 866 infants screened for vitamin D status at birth. Data were analyzed from June 2021 to November 2022. INTERVENTIONS: Capillary blood was collected 24 to 36 hours after birth to measure serum total 25(OH)D concentrations. Infants with 25(OH)D concentrations less than 50 nmol/L were randomized to receive either 1000 IU or 400 IU per day of oral vitamin D(3) supplementation from age 1 to 12 months. Infants with 25(OH)D concentrations of 50 nmol/L or greater formed a reference group. MAIN OUTCOMES AND MEASURES: Measures at age 1, 3, 6, and 12 months were preplanned and included whole-body bone mineral content, lumbar spine bone mineral content, and bone mineral density using dual-energy x-ray absorptiometry, and serum 25(OH)D(3) using liquid chromatography tandem mass spectrometry. RESULTS: Of 139 included infants, 81 (58.3%) were male, and the median (IQR) gestational age at birth was 39.6 (38.9-40.6) weeks. A total of 49 infants were included in the 1000 IU per day group, 49 infants in the 400 IU per day group, and 41 in the reference group. Mean (SD) whole-body bone mineral content was not different between trial groups over time (1000 IU per day, 173.09 [2.36] g; 400 IU per day, 165.94 [66.08] g). Similarly, no differences were observed in lumbar spine bone mineral content or density. Mean (SD) serum 25(OH)D(3) concentrations were significantly higher in the 1000 IU per day group from age 3 to 12 months (3 months, 115.2 [35.3] nmol/L; 6 months, 121.6 [34.4] nmol/L; 12 months, 99.6 [28.8] nmol/L) compared with the 400 IU per day trial group (3 months, 77.4 [23.3] nmol/L; 6 months, 85.1 [18.6] nmol/L; 12 months, 82.3 [14.3] nmol/L). CONCLUSIONS AND RELEVANCE: In this study, a higher dose of vitamin D supplementation in infants born with 25(OH)D concentrations less than 50 nmol/L did not present advantages to bone mass in infancy. This study supports a standard dose of 400 IU per day of vitamin D supplementation for breastfed infants in Montreal. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02563015
format Online
Article
Text
id pubmed-9926359
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-99263592023-02-15 Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial Gharibeh, Nathalie Razaghi, Maryam Vanstone, Catherine A. Sotunde, Olusola F. Glenn, Laura Mullahoo, Kristina Farahnak, Zahra Khamessan, Ali Wei, Shu Qin McNally, Dayre Rauch, Frank Jones, Glenville Kaufmann, Martin Weiler, Hope A. JAMA Pediatr Original Investigation IMPORTANCE: The dose of supplemental vitamin D needed in infants born with serum 25-hydroxyvitamin D (25[OH]D) concentrations less than 50 nmol/L (ie, 20 ng/mL) is unclear. OBJECTIVE: To determine whether a higher dose (1000 IU vs 400 IU per day) is required in infants born with 25(OH)D concentrations less than 50 nmol/L for bone mineral accretion across infancy. DESIGN, SETTING, AND PARTICIPANTS: In this prespecified secondary analysis of a double-blinded randomized clinical trial, conducted from March 2016 to March 2019 in a single center in Greater Montreal, Quebec, Canada, a consecutive sample of 139 healthy term singletons were recruited from 866 infants screened for vitamin D status at birth. Data were analyzed from June 2021 to November 2022. INTERVENTIONS: Capillary blood was collected 24 to 36 hours after birth to measure serum total 25(OH)D concentrations. Infants with 25(OH)D concentrations less than 50 nmol/L were randomized to receive either 1000 IU or 400 IU per day of oral vitamin D(3) supplementation from age 1 to 12 months. Infants with 25(OH)D concentrations of 50 nmol/L or greater formed a reference group. MAIN OUTCOMES AND MEASURES: Measures at age 1, 3, 6, and 12 months were preplanned and included whole-body bone mineral content, lumbar spine bone mineral content, and bone mineral density using dual-energy x-ray absorptiometry, and serum 25(OH)D(3) using liquid chromatography tandem mass spectrometry. RESULTS: Of 139 included infants, 81 (58.3%) were male, and the median (IQR) gestational age at birth was 39.6 (38.9-40.6) weeks. A total of 49 infants were included in the 1000 IU per day group, 49 infants in the 400 IU per day group, and 41 in the reference group. Mean (SD) whole-body bone mineral content was not different between trial groups over time (1000 IU per day, 173.09 [2.36] g; 400 IU per day, 165.94 [66.08] g). Similarly, no differences were observed in lumbar spine bone mineral content or density. Mean (SD) serum 25(OH)D(3) concentrations were significantly higher in the 1000 IU per day group from age 3 to 12 months (3 months, 115.2 [35.3] nmol/L; 6 months, 121.6 [34.4] nmol/L; 12 months, 99.6 [28.8] nmol/L) compared with the 400 IU per day trial group (3 months, 77.4 [23.3] nmol/L; 6 months, 85.1 [18.6] nmol/L; 12 months, 82.3 [14.3] nmol/L). CONCLUSIONS AND RELEVANCE: In this study, a higher dose of vitamin D supplementation in infants born with 25(OH)D concentrations less than 50 nmol/L did not present advantages to bone mass in infancy. This study supports a standard dose of 400 IU per day of vitamin D supplementation for breastfed infants in Montreal. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02563015 American Medical Association 2023-02-13 2023-04 /pmc/articles/PMC9926359/ /pubmed/36780180 http://dx.doi.org/10.1001/jamapediatrics.2022.5837 Text en Copyright 2023 Gharibeh N et al. JAMA Pediatrics. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Gharibeh, Nathalie
Razaghi, Maryam
Vanstone, Catherine A.
Sotunde, Olusola F.
Glenn, Laura
Mullahoo, Kristina
Farahnak, Zahra
Khamessan, Ali
Wei, Shu Qin
McNally, Dayre
Rauch, Frank
Jones, Glenville
Kaufmann, Martin
Weiler, Hope A.
Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title_full Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title_fullStr Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title_full_unstemmed Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title_short Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title_sort effect of vitamin d supplementation on bone mass in infants with 25-hydroxyvitamin d concentrations less than 50 nmol/l: a prespecified secondary analysis of a randomized clinical trial
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926359/
https://www.ncbi.nlm.nih.gov/pubmed/36780180
http://dx.doi.org/10.1001/jamapediatrics.2022.5837
work_keys_str_mv AT gharibehnathalie effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT razaghimaryam effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT vanstonecatherinea effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT sotundeolusolaf effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT glennlaura effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT mullahookristina effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT farahnakzahra effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT khamessanali effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT weishuqin effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT mcnallydayre effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT rauchfrank effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT jonesglenville effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT kaufmannmartin effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT weilerhopea effectofvitamindsupplementationonbonemassininfantswith25hydroxyvitamindconcentrationslessthan50nmollaprespecifiedsecondaryanalysisofarandomizedclinicaltrial